Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart…
New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040There are currently no FDA-approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North…